What does this research mean for the field?

Observational studies consistently indicate a reduction in atrial fibrillation risk with SGLT2 inhibitors, whereas randomized controlled trials show inconsistent and mixed results. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

September 12, 2024Journal of Clinical MedicineOpen Access

The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review

Q: What is the clinical evidence from this study?

Study design: Review. Population: Atrial Fibrillation. Intervention: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs. Placebo or active comparators (e.g., DPP4is, GLP-1RAs). Primary outcome: Incidence of new-onset and recurrence of atrial fibrillation.

View Full Paper

Ask AI

Bookmark

Key result

SGLT2 inhibitors show observational AF reductions, but randomized trials yield mixed results.

Why the study?

SGLT2 inhibitors have been proposed for managing AF, but current evidence from animal models and clinical studies remains inconclusive.

Do SGLT2 inhibitors reduce the incidence of new-onset and recurrence of atrial fibrillation in patients with T2DM and heart failure?

Structured PICO

Do SGLT2 inhibitors reduce the incidence of new-onset and recurrence of atrial fibrillation in patients with T2DM and heart failure?

Population

A narrative review analyzing the impact of SGLT2 inhibitors on the prevalence, incidence, and recurrence of atrial fibrillation in patients with type 2 diabetes and heart failure.

Intervention

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) as a class

Comparator

Placebo or active comparators (e.g., DPP4 inhibitors, GLP-1 receptor agonists) depending on the reviewed study

Outcome

Prevalence, incidence of new-onset, and recurrence of atrial fibrillation (AF)hard clinical

While observational data strongly suggest SGLT2 inhibitors reduce the risk of incident and recurrent atrial fibrillation, mixed results from RCTs highlight the need for definitive prospective trials.

Limitations

Observational studies may suffer from bias and confounding factors despite propensity score matching.
RCTs are fewer in number and their outcomes are heterogeneous and conflicting.
Data about AF incidence was typically not a pre-defined endpoint in the included studies and was reported as adverse events, risking under-reporting.
There is significant heterogeneity in study outcomes, population characteristics, follow-up duration, and specific SGLT2is used.
Heterogeneity in study outcomes
Heterogeneity in population characteristics
Heterogeneity in follow-up duration
Differences in specific SGLT2is used
Potential biases in observational studies

Implication

SGLT2 inhibitors should not yet alter AF prevention in T2DM or HF; leaves open definitive efficacy pending rigorous RCTs.

Abstract

Atrial fibrillation (AF) is the most prevalent arrhythmia among adults worldwide, frequently co-occurring with comorbidities such as Heart Failure (HF) and Type 2 Diabetes Mellitus (T2DM). This association contributes to increased morbidity and mortality, elevated healthcare costs, and diminished quality of life. Consequently, preventing or delaying the onset and recurrence of AF is crucial for reducing the incidence of complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), due to their multifaceted pharmacological actions, have been proposed as potential therapeutic agents in the management of AF. However, current evidence from both animal models and clinical studies remains inconclusive. This narrative literature review aims to provide a comprehensive analysis of existing evidence on the impact of SGLT2is on the prevalence, incidence of new-onset, and recurrence of AF in diabetic populations and patients with HF. Numerous observational studies, predominantly retrospective, suggest a consistent reduction in AF risk with SGLT2is, while randomized controlled trials (RCTs) have yielded mixed results, with some demonstrating benefits and others not reaching statistical significance. The heterogeneity in study outcomes, population characteristics, follow-up duration, and specific SGLT2is used, as well as potential biases, underscore the need for further extensive and rigorous RCTs to establish definitive conclusions and elucidate the underlying mechanisms.

Discussion

No takes yet. Share an insight, caveat, or question.

Figures from the paper

Published by Journal of Clinical Medicine · CC BY

Cite This Study

Stachteas et al. (2024) conducted a review in Atrial Fibrillation. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs. Placebo or active comparators (e.g., DPP4is, GLP-1RAs) was evaluated on Incidence of new-onset and recurrence of atrial fibrillation. Observational studies consistently suggest a reduction in atrial fibrillation risk with SGLT2 inhibitors, whereas randomized controlled trials have yielded mixed results.

synapsesocial.com/papers/6a20104b9d62e9997c04bd25 https://doi.org/10.3390/jcm13185408